Gou GE, Li T, Liu CR, Meng T, Li YP. Potential mechanisms and therapeutic prospects of the association between Helicobacter pylori infection and metabolic dysfunction-associated steatohepatitis. World J Hepatol 2025; 17(1): 101798 [DOI: 10.4254/wjh.v17.i1.101798]
Corresponding Author of This Article
Ya-Ping Li, MD, PhD, Doctor, Department of Infectious Diseases, The Second Affiliated Hospital of Xi'an Jiaotong University, No. 157 West 5th Road, Xincheng District, Xi'an 710004, Shaanxi Province, China. liyaping8605@xjtu.edu.cn
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. Jan 27, 2025; 17(1): 101798 Published online Jan 27, 2025. doi: 10.4254/wjh.v17.i1.101798
Potential mechanisms and therapeutic prospects of the association between Helicobacter pylori infection and metabolic dysfunction-associated steatohepatitis
Guo-E Gou, Ting Li, Chen-Rui Liu, Ting Meng, Ya-Ping Li
Guo-E Gou, Ting Li, Chen-Rui Liu, Ting Meng, Ya-Ping Li, Department of Infectious Diseases, Xi'an Jiaotong University Second Affiliated Hospital, Xi’an 710004, Shaanxi Province, China
Author contributions: Li YP conceptualized and outlined the manuscript; Both Li YP and Gou GE contributed to the writing, editing, illustration, and literature review, which were collaboratively conducted by Gou GE and Li T; Liu CR assisted with figure preparation, whereas Meng T supported the literature review.
Supported by Basic and Clinical Integration Project of Xi’an Jiaotong University, No. YXJLRH2022067.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ya-Ping Li, MD, PhD, Doctor, Department of Infectious Diseases, The Second Affiliated Hospital of Xi'an Jiaotong University, No. 157 West 5th Road, Xincheng District, Xi'an 710004, Shaanxi Province, China. liyaping8605@xjtu.edu.cn
Received: September 27, 2024 Revised: November 13, 2024 Accepted: November 22, 2024 Published online: January 27, 2025 Processing time: 101 Days and 17.9 Hours
Abstract
Helicobacter pylori (H. pylori) infection is a known inducer of various gastrointestinal diseases, including gastritis, gastric ulcers, and gastric cancer. However, in recent years, research on the potential association between H. pylori infection and metabolic dysfunction-associated steatohepatitis (MASH) has been scarce. This large-scale multicenter study, covering more than 360 hospitals across 26 medical systems in the United States, systematically evaluated the association between H. pylori infection and MASH. This paper reviews the innovative aspects of this study, discusses its significance in the current research field of H. pylori and liver diseases, analyzes potential molecular mechanisms, and suggests future research directions and therapeutic prospects.
Core Tip: The association between Helicobacter pylori (H. pylori) infection and metabolic dysfunction-associated steatohepatitis (MASH) has been confirmed in large-scale multicenter studies, suggesting that H. pylori is an independent risk factor for MASH development. This study revealed that H. pylori may influence MASH through chronic inflammation, insulin resistance, and the gut-liver axis, providing new insights into the pathogenesis of metabolic liver diseases. On the basis of these findings, H. pylori eradication therapy may offer a novel strategy for the prevention and treatment of MASH. Future research should focus on the molecular mechanisms linking H. pylori infection and MASH, particularly genetic susceptibility, gene polymorphisms, and metabolic pathways, in the treatment of MASH.
